Severe Asthma Proves Too Much Of A Challenge For Vectura
Executive Summary
An ambitious trial of a budesonide-based drug/device combo for uncontrolled asthma has failed, but Vectura is upbeat as it switches resources to a potential pediatric asthma treatment.
You may also be interested in...
Private Equity Eyes Pharma As Vectura Gets Snapped Up By Carlyle
Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.
Watch Out GSK: Vectura And Hikma Target Ellipta Portfolio
Vectura and Hikma could have generic versions of GSK's Ellipta portfolio ready for marketing when patent protection expires.
Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard
FDA issued a complete response letter for Hikma's ANDA to market a generic version of GSK's Advair, the second application to be rejected by FDA.